We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

By LabMedica International staff writers
Posted on 19 Feb 2025

Sepsis is the leading cause of death and the most expensive condition treated in U. More...

S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early detection critical. Now, a new study has shown that a rapid sepsis diagnostic test can reduce care costs and improve the efficiency of sepsis management at a large academic medical center in the U.S.

The study was conducted by Our Lady of the Lake Regional Medical Center (Baton Rouge, LA, USA) to evaluate Cytovale’s (South San Francisco, CA, USA) IntelliSep test and presented at the International Symposium on Intensive Care and Emergency Medicine Conference. IntelliSep is the first FDA-cleared rapid diagnostic test for sepsis, designed for use in the Emergency Department to identify the dysregulated host response to infection that signals sepsis. The test produces results in approximately 8 minutes from a standard blood draw and can be easily integrated into existing care workflows.

The study, which examined the impact of IntelliSep on sepsis care for patients presenting to the Emergency Department, included 196 control patients and 413 intervention patients at Our Lady of the Lake Regional Medical Center. Patients whose care was guided by IntelliSep testing spent less time in the hospital and experienced more efficient triage, resulting in significant cost savings. On average, IntelliSep-informed care resulted in cost savings of USD 3,624 per inpatient admitted to the intensive care unit (ICU), associated with a 2.42-day reduction in average length of stay (LOS) for these patients; USD 1,930 per non-ICU inpatient, with a 1.28-day reduction in average LOS; and USD 243 per observation patient. Overall, the study demonstrated an average cost saving of USD 1,429 per patient across the entire cohort tested with IntelliSep. In addition to these findings, the medical center also reported a decrease in needle sticks and antibiotic exposure for patients, thanks to more accurate sepsis detection.

"IntelliSep is an entirely new way of approaching sepsis detection. It creates the standard for hospitals to rapidly cut through clinical uncertainty and definitively identify sepsis to improve patient care," said Christopher Thomas, M.D., vice president and chief quality officer at Franciscan Missionaries of Our Lady Health System and Critical Care Physician at Louisiana State University Health Sciences Center. "Roughly 20% of patients entering the ED are at risk for sepsis and delayed diagnosis often leads to lengthy hospital stays and increased use of resources. With IntelliSep, we're able to improve patient centered outcomes and accelerate time to treatment for high-risk patients. The combination of cost savings for our patients, paired with a faster time to return home to their families, is a game changer."

Related Links:
Cytovale
Our Lady of the Lake Regional Medical Center


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.